Shawn Singh

CIK: 0001412071

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)5 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

VTGN

Vistagen Therapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

VTGN
Vistagen Therapeutics, Inc.
Jun 30, 2026
Award(A)
Direct
36.8K shares at avg. $0.19$7K
VTGN
Vistagen Therapeutics, Inc.
Apr 7, 2026
Award(A)
Incentive Stock Option (right to buy)
Direct
3.7K shares-
VTGN
Vistagen Therapeutics, Inc.
Apr 7, 2026
Award(A)
Non-Qualified Stock Option (right to buy)
Direct
71.3K shares-
VTGN
Vistagen Therapeutics, Inc.
Jun 30, 2025
Award(A)
Direct
7.5K shares at avg. $1.70$13K
VTGN
Vistagen Therapeutics, Inc.
Jun 23, 2025
Award(A)
Stock Option (Right to Buy)
Direct
300K shares-

		Type	Shares	Price		Ownership
Jun 30, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A)	36,818	$0.19	$7,073	Direct
Apr 7, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A) Incentive Stock Option (right to buy)	3,732	-	-	Direct
Apr 7, 2026	VTGN Vistagen Therapeutics, Inc.	Award(A) Non-Qualified Stock Option (right to buy)	71,268	-	-	Direct
Jun 30, 2025	VTGN Vistagen Therapeutics, Inc.	Award(A)	7,541	$1.70	$12,820	Direct
Jun 23, 2025	VTGN Vistagen Therapeutics, Inc.	Award(A) Stock Option (Right to Buy)	300,000	-	-	Direct

1-5 of 5 transactions

About Singh Shawn

Singh Shawn (SEC CIK 0001412071) files insider reports with the SEC as President and CEO of Vistagen Therapeutics, Inc. (VTGN).

Signal8 holds 4 ownership filings by Singh Shawn, all Form 4s, filed between Jun 25, 2025 and Jul 2, 2026. Those filings report 5 transactions, from Jun 23, 2025 to Jun 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Singh Shawn's filings is in SOUTH SAN FRANCISCO, CA.

Recent filings by Singh Shawn

Jun 30, 2026: Grant or award of VTGN shares (Form 4, code A).
Apr 7, 2026: Grants or awards of VTGN derivative securities (2 lines, Form 4, code A).
Jun 30, 2025: Grant or award of VTGN shares (Form 4, code A).
Jun 23, 2025: Grant or award of VTGN derivative securities (Form 4, code A).

Other insiders filing for Vistagen Therapeutics, Inc. (VTGN)

Williamson Douglas J, Officer
Adler Reid G., Chief Legal Officer
Tressler Nick B., Chief Financial Officer
Angelov Angel S, Chief Medical Officer
Prince Joshua S., Chief Operating Officer
Cote Elissa S., Chief Corp Development Officer

How to read Form 4 transaction codes